NCT03412877 2026-04-14
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
285 trialsNCT04877821 2026-04-02
NeoSACT
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT02654119 2026-03-23
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
Phase 2 Completed
NCT06797635 2026-03-13
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT01174121 2026-03-04
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06318897 2026-03-04
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06802757 2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT00003042 2026-02-20
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT07423611 2026-02-20
RACE
Fudan University
Phase 2 Not yet recruiting
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT06291064 2026-02-17
TARMAC
University of Chicago
Phase 2 Recruiting
NCT03301350 2026-02-13
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT02624973 2026-02-12
PETREMAC
Haukeland University Hospital
Phase 2 Active not recruiting
NCT01796197 2026-02-05
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02876302 2026-02-04
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT04872985 2026-01-06
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT06690840 2026-01-05
AZALEA
European Institute of Oncology
Phase 2 Recruiting
NCT06085742 2025-12-19
BRE-08
University of Illinois at Chicago
Phase 2 Recruiting
NCT06107673 2025-12-11
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT06409390 2025-12-04
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT01898117 2025-11-26
Triple-B
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT02623972 2025-11-25
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03449108 2025-11-21
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT07016399 2025-10-30
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT04443348 2025-10-14
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT06042569 2025-10-09
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT05645380 2025-10-07
NeoTRACT
University of Kansas Medical Center
Phase 2 Recruiting
NCT00861705 2025-09-30
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00295893 2025-09-25
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06245889 2025-09-23
NeoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03515798 2025-09-12
PELICAN
Institut Paoli-Calmettes
Phase 2 Active not recruiting
NCT04243616 2025-09-05
CemiHALT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT02957968 2025-08-28
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Phase 2 Active not recruiting
NCT05582499 2025-08-22
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT06155331 2025-08-19
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Tanta University
Phase 2 Completed
NCT04083963 2025-07-10
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
University of Illinois at Chicago
Phase 2 Active not recruiting
NCT06500208 2025-06-26
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06964906 2025-05-11
NeoHunter
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT01670500 2025-04-09
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT05498896 2025-03-10
BARBICAN
Queen Mary University of London
Phase 2 Active not recruiting
NCT05020860 2025-02-27
RESPONSE
Baylor Breast Care Center
Phase 2 Recruiting
NCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT06705127 2024-11-26
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT03971045 2024-11-19
PERICLES
European Institute of Oncology
Phase 2 Recruiting